U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C29H27F3N6O.ClH
Molecular Weight 569.02
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PONATINIB HYDROCHLORIDE

SMILES

Cl.CN1CCN(CC2=CC=C(NC(=O)C3=CC=C(C)C(=C3)C#CC4=CN=C5C=CC=NN45)C=C2C(F)(F)F)CC1

InChI

InChIKey=BWTNNZPNKQIADY-UHFFFAOYSA-N
InChI=1S/C29H27F3N6O.ClH/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37;/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39);1H

HIDE SMILES / InChI

Molecular Formula C29H27F3N6O
Molecular Weight 532.5595
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Ponatinib (trade name Iclusig, previously AP24534) is developed by ARIAD Pharmaceuticals for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome–positive (Ph ) acute lymphoblastic leukemia (ALL). Ponatinib has been designed to be effective against these types of tumors. The United States Food and Drug Administration approved the drug as a candidate in 2012, but temporarily suspended sales on 31 October 2013 because of "the risk of life-threatening blood clots and severe narrowing of blood vessels". This suspension was partially lifted on Dec. 20, 2013 with ponatinib being issued revised prescribing information, a new "Black Box Warning" and a "Risk Evaluation and Mitigation Strategy" in place to better evaluate the risks and benefits of using the drug. Ponatinib is an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.

CNS Activity

Originator

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: 12345.0
Gene ID: 25400.0
Gene Symbol: Camk2a
Target Organism: Rattus norvegicus (Rat)
Target ID: P00594
Gene ID: NA
Gene Symbol: PLA2G1B
0.4 nM [IC50]
Target ID: GO:0000001
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Iclusig

Approved Use

To treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.

Launch Date

1.60194245E12
Palliative

Launch Date

0.0
Inactive Ingredient

Approved Use

To treat adults with chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph ALL), two rare blood and bone marrow diseases.

Launch Date

1.36062724E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
73 ng/mL
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PONATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
183.1 nM
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PONATINIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
73 ng/mL
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PONATINIB unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1253 ng × h/mL
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PONATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
2856 nM × h
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PONATINIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1253 ng × h/mL
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PONATINIB unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
24 h
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PONATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
19.7 h
60 mg 1 times / day steady-state, oral
dose: 60 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PONATINIB blood
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PONATINIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
1%
45 mg 1 times / day steady-state, oral
dose: 45 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
PONATINIB unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Disc. AE: Infection, Thrombocytopenia...
AEs leading to
discontinuation/dose reduction:
Infection (1%)
Thrombocytopenia (30%)
Neutropenia (13%)
Lipase increased (12%)
Rash (11%)
Abdominal pain (11%)
Pancreatitis (6%)
ALT increased (6%)
AST increased (6%)
GGT increased (6%)
Myocardial ischemia (serious, 5%)
Arterial thrombosis (serious, 34 patients)
Ischemia cerebral (serious, 8 patients)
Peripheral arterial ischemia (serious, 7 patients)
Arterial stenosis (serious, 5%)
Myocardial infarction (serious, 14 patients)
Cerebrovascular event (serious, 2%)
Extremity necrosis (serious, 3 patients)
Thrombocytopenia (4%)
Sources:
60 mg 1 times / day multiple, oral
Recommended,MTD,Overdose
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Population Size: 19
Sources:
Disc. AE: Ischemia...
AEs leading to
discontinuation/dose reduction:
Ischemia (serious, 4 patients)
Sources:
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy
n = 19
DLT: Blood amylase increased, Fatigue...
Dose limiting toxicities:
Blood amylase increased (grade 3-4, 4 patients)
Fatigue (grade 3, 1 patient)
Alanine aminotransferase increased (grade 3, 1 patient)
Aspartate aminotransferase increased (grade 3, 1 patient)
Lipase increased (grade 3-4, 4 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Infection 1%
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Abdominal pain 11%
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Rash 11%
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Lipase increased 12%
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Neutropenia 13%
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Thrombocytopenia 30%
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Thrombocytopenia 4%
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
ALT increased 6%
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
AST increased 6%
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
GGT increased 6%
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Pancreatitis 6%
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Myocardial infarction serious, 14 patients
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Cerebrovascular event serious, 2%
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Extremity necrosis serious, 3 patients
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Arterial thrombosis serious, 34 patients
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Arterial stenosis serious, 5%
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Myocardial ischemia serious, 5%
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Peripheral arterial ischemia serious, 7 patients
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Ischemia cerebral serious, 8 patients
Disc. AE
45 mg 1 times / day steady, oral
Recommended
Dose: 45 mg, 1 times / day
Route: oral
Route: steady
Dose: 45 mg, 1 times / day
Sources:
unhealthy
n = 449
Health Status: unhealthy
Population Size: 449
Sources:
Ischemia serious, 4 patients
Disc. AE
60 mg 1 times / day multiple, oral
Recommended,MTD,Overdose
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy
n = 19
Health Status: unhealthy
Population Size: 19
Sources:
Alanine aminotransferase increased grade 3, 1 patient
DLT
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy
n = 19
Aspartate aminotransferase increased grade 3, 1 patient
DLT
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy
n = 19
Fatigue grade 3, 1 patient
DLT
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy
n = 19
Blood amylase increased grade 3-4, 4 patients
DLT
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy
n = 19
Lipase increased grade 3-4, 4 patients
DLT
60 mg 1 times / day multiple, oral
Dose: 60 mg, 1 times / day
Route: oral
Route: multiple
Dose: 60 mg, 1 times / day
Sources:
unhealthy
n = 19
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
little [IC50 10.8 uM]
little [IC50 11.6 uM]
little [IC50 13.3 uM]
little [IC50 5.2 uM]
little [IC50 5.6 uM]
little [IC50 6.1 uM]
little [IC50 8.3 uM]
no
no
no
no
no
no
yes [Activation 0.6 uM]
yes [IC50 0.013 uM]
yes [IC50 0.49 uM]
yes [IC50 32 uM]
Drug as victimTox targets

Tox targets

PubMed

PubMed

TitleDatePubMed
[Therapy of sickle cell anemia by alkalies and magnesium salts. Presentation of a case].
1967 Jun
Inhibitors of ABL and the ABL-T315I mutation.
2008
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
2009 Nov 6
Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
2010 Jun 24
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.
2011 Jun 15
Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.
2011 Jun 15
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
2011 Nov 10
The BCR-ABL35INS insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
2011 Nov 10
Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.
2012 Jul
Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases.
2012 Jul
Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models.
2012 Mar
Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
2012 May
The ins and outs of bcr-abl inhibition.
2012 May
Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
2012 May
Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.
2013 Jan
Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.
2013 Jan
Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome.
2013 Jan
Ponatinib suppresses the development of myeloid and lymphoid malignancies associated with FGFR1 abnormalities.
2013 Jan
Patents

Sample Use Guides

In Vivo Use Guide
Sources: uri2
Curator's Comment: comment
45 mg taken orally once daily with or without food
Route of Administration: Oral
In Vitro Use Guide
Ponatinib inhibited the in vitro tyrosine kinase activity of ABL and T315I mutant ABL with IC50 concentrations of 0.4 and 2.0 nM, respectively. Ponatinib inhibited the in vitro activity of additional kinases with IC50 concentrations between 0.1 and 20 nM, including members of the VEGFR, PDGFR, FGFR, EPH receptors and SRC families of kinases, and KIT, RET, TIE2, and FLT3. Ponatinib inhibited the in vitro viability of cells expressing native or mutant BCR-ABL, including T315I.
Substance Class Chemical
Created
by admin
on Thu Jul 06 01:34:26 UTC 2023
Edited
by admin
on Thu Jul 06 01:34:26 UTC 2023
Record UNII
96R6PU3D8J
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PONATINIB HYDROCHLORIDE
ORANGE BOOK   USAN   WHO-DD  
USAN  
Official Name English
PONATINIB HYDROCHLORIDE [JAN]
Common Name English
3-(2-(IMIDAZO(1,2-B)PYRIDAZIN-3-YL)ETHYNYL)-4-METHYL-N-(4-((4-METHYLPIPERAZIN-1- YL)METHYL)-3-(TRIFLUOROMETHYL)PHENYL)BENZAMIDE MONOHYDROCHLORIDE
Systematic Name English
BENZAMIDE, 3-(2-IMIDAZO(1,2-B)PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-(4-((4-METHYL-1- PIPERAZINYL)METHYL)-3-(TRIFLUOROMETHYL)PHENYL)-, HYDROCHLORIDE (1:1)
Systematic Name English
ICLUSIG
Brand Name English
AP24534 HCL
Code English
AP-24534 HCL
Code English
PONATINIB HYDROCHLORIDE [ORANGE BOOK]
Common Name English
Ponatinib hydrochloride [WHO-DD]
Common Name English
PONATINIB HYDROCHLORIDE [USAN]
Common Name English
PONATINIB HYDROCHLORIDE [MI]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/14/1421
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
NCI_THESAURUS C1742
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
EMA ASSESSMENT REPORTS ICLUSIG (AUTHORIZED: LEUKEMIA, LYMPHOID)
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
NCI_THESAURUS C155700
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
Code System Code Type Description
ChEMBL
CHEMBL1171837
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
PRIMARY
MERCK INDEX
M11700
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
PRIMARY
USAN
XX-35
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
PRIMARY
FDA UNII
96R6PU3D8J
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
PRIMARY
PUBCHEM
46908927
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
PRIMARY
EVMPD
SUB121686
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
PRIMARY
CAS
1114544-31-8
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
PRIMARY
RXCUI
1364953
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID50149655
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
PRIMARY
DAILYMED
96R6PU3D8J
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
PRIMARY
NCI_THESAURUS
C78194
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
PRIMARY
DRUG BANK
DBSALT000142
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
PRIMARY
SMS_ID
100000144869
Created by admin on Thu Jul 06 01:34:26 UTC 2023 , Edited by admin on Thu Jul 06 01:34:26 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
AUC 0-24 hrs PHARMACOKINETIC Dosage
PHARMACOKINETIC
Route of Adminstration
PHARMACOKINETIC
Tmax PHARMACOKINETIC
Cmax PHARMACOKINETIC Dosage
PHARMACOKINETIC
Route of Administration
PHARMACOKINETIC